Efficacy News and Research

RSS

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

University of Chicago scientists develop new technique to accurately measure epigenetic changes

One of the most widely used tools in epigenetics research - the study of how DNA packaging affects gene expression - is chromatin immunoprecipitation (ChIP), a technique that allows researchers to examine interactions between specific proteins and genomic regions. However, ChIP is a relative measurement, and has significant limitations that can lead to errors, poor reproducibility and an inability to be compared between experiments.

4 Jun 2015

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer, also known as Hepatocellular Carcinoma (HCC).

4 Jun 2015

Steven Schiff wins NIH Director's Pioneer Award to reduce infant deaths from neonatal sepsis

Steven Schiff, professor of neurosurgery and Brush Chair Professor of Engineering in Engineering Science and Mechanics, has received a $4.1 million National Institutes of Health Director's Pioneer Award, for research aimed at reducing the number of infant deaths from neonatal sepsis in developing countries by identifying the roots of infection, from season of birth to home environment.

4 Jun 2015

MR Solutions provides advanced preclinical imaging solution at Manchester University

This new state of the art preclinical imaging system was developed, supplied and installed by MR Solutions of Guildford, Surrey and supported by the UK Regenerative Medicine Platform with a grant for equipment to the Stem Cell Safety Hub.

From MR Solutions 3 Jun 2015

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian Medical Systems today announced that it has been selected to equip and service the new multi-room HollandPTC in Delft with the Varian ProBeam proton therapy system. The company will book the equipment part of the order in its fiscal 2015 third quarter.

3 Jun 2015

Researchers conduct noise output measurements on electric cars to improve safety of blind and visually-impaired people

The Professional Development and Research Institute on Blindness at Louisiana Tech University is conducting human trials to determine if electric and hybrid electric vehicles traveling at low speeds provide sufficient sound to be safe for pedestrians, especially those who are blind and visually-impaired.

3 Jun 2015

Using graphene as alternative coating for catheters to improve chemotherapy delivery

A new study published in IOP Publishing's journal 2D Materials has proposed using graphene as an alternative coating for catheters to improve the delivery of chemotherapy drugs.

3 Jun 2015

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, today announced that it will collaborate with Celgene Cellular Therapeutics (CCT) (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

3 Jun 2015

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Two phase III trials published in The New England Journal of Medicine support the use of nivolumab in patients with treatment-naïve metastatic melanoma and in those with squamous non-small-cell lung cancer who have failed first-line chemotherapy.

2 Jun 2015

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Results of two clinical trials reported at the American Society for Clinical Oncology Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically in the context of PD1 signaling that some tumors use to avoid immune system attack. Dr. Rene Gonzalez, MD, investigator at the University of Colorado Cancer Center and director of the Melanoma Research Clinics at the CU School of Health, is an author of both studies.

2 Jun 2015

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Hospira, Inc., a global leader in biosimilars, today announced that its partner, Celltrion – a global biopharmaceutical company – has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil.

2 Jun 2015

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

2 Jun 2015

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy.

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

Efficacy News and Research

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

University of Chicago scientists develop new technique to accurately measure epigenetic changes

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Steven Schiff wins NIH Director's Pioneer Award to reduce infant deaths from neonatal sepsis

MR Solutions provides advanced preclinical imaging solution at Manchester University

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Researchers conduct noise output measurements on electric cars to improve safety of blind and visually-impaired people

Using graphene as alternative coating for catheters to improve chemotherapy delivery

BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News